TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…The challenge to prevent Parkinson’s Disease with a new in vitro approach
Objective: This research line aims to perform a compound screening on the prophylactic capacity of a high number of nutraceuticals and drugs to prevent dopaminergic…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques
Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity
Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…Hesperidin lessens rotenone induced Parkinson diseases angiogenesis in nigrostriatal neuronal death through the AMPK/FOXO3 Signaling pathway
Objective: This study is to investigate the neuroprotective effect of HSP in a mouse model of Parkinson's disease (PD) caused by rotenone, with an emphasis…Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model
Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease
Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Real-World, USA Experience
Objective: Here, we present preliminary outcomes from an on-going, prospective, multicenter outcomes registry conducted in the USA consisting of patients implanted with directional Deep Brain…
- « Previous Page
- 1
- …
- 410
- 411
- 412
- 413
- 414
- …
- 1942
- Next Page »